Citius Oncology, Inc.

The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company that develops and sells specialized cancer treatments. Its main goal is to become a market leader by creating new therapies that have lower development and clinical risks, and strong competitive advantages through intellectual property and regulatory protection. This includes new versions of drugs already approved with significant safety and effectiveness data, or new uses for existing approved treatments. The Company's primary product is LYMPHIR TM, an engineered IL-2 diphtheria toxin fusion protein, used to treat patients with persistent or recurrent CTCL, a rare type of non-Hodgkin lymphoma. LYMPHIR received approval from the U.S. Food and Drug Administration (FDA) in August 2024 and was introduced to the market in December 2025. The Company plans to sell its products directly in the U.S. and collaborate with partners to market products outside the U.S. It has created a small, focused oncology sales team, initially for LYMPHIR, targeting major cancer centers in key regions. This approach is expected to generate direct sales revenue and royalty income. On August 23, 2021, Citius Pharma created Citius Acquisition Corp. ("SpinCo") as a wholly-owned subsidiary for the acquisition of LYMPHIR. SpinCo started operations in April 2022 when Citius Pharma transferred the LYMPHIR-related assets, including license agreements with Eisai Co., Ltd. and asset purchase agreements with Dr. Reddy's Laboratories SA.